中国药业2025，Vol.34Issue(10)：116-119,4.DOI:10.3969/j.issn.1006-4931.2025.10.025
达格列净联合沙库巴曲缬沙坦钠用于急性心肌梗死PCI术后临床观察
Clinical Observation of Dapagliflozin Combined with Sacubitril Valsartan Sodium in the Treatment of Acute Myocardial Infarction After PCI Surgery
摘要
Abstract
Objective To investigate the clinical efficacy of dapagliflozin combined with sackubactril valsartan sodium in the treatment of acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI)surgery,and the effect on left ventricular remodeling and peripheral blood miRNAs.Methods A total of 91 patients underwent PCI for AMI admitted to the hospital from January 2022 to September 2023 were selected and divided into the observation group(41 cases)and the control group(50 cases)according to different treatment.Both groups were treated with conventional antithrombotic therapy and Sackubactril Valsartan Sodium Tablets,and the observation group was additionally given Dapagliflozin Tablets.Both groups were treated continuously for 3 weeks.Results The total clinical effective rate in the observation group was 94.00%,which was significantly higher than 78.05%in the control group(P<0.05).After treatment,the hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),left ventricular mass index(LVMI),interventricular septal end-systolic thickness(IVSS),left ventricular posterior wall end-systolic thickness(LVPWs),brain natriuretic peptide(BNP),cardiac troponin I(cTnI)and peripheral blood miR-492,miR-302b,miR-23a levels were significantly decreased,while the left ventricular ejection fraction(LVEF)was significantly increased in the two groups(P<0.05),and the above indicators in the observation group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions in the two groups was comparable(8.00%vs.12.50,P>0.05).Conclusion Dapagliflozin combined with Sackubactril Valsartan Sodium in the treatment of AMI after PCI surgery can effectively reduce the expression level of serum miRNAs,inhibit left ventricular remodeling,improve the heart function,reduce the occurrence of adverse cardiovascular events and improve prognosis.关键词
达格列净/沙库巴曲缬沙坦/急性心肌梗死/经皮冠状动脉介入术/左心室重构/miRNA/临床疗效Key words
dapagliflozin/sacubactril valsartan sodium/acute myocardial infarction/percutaneous coronary intervention/left ventricular remodeling/miRNAs/clinical efficacy分类
药学引用本文复制引用
夏木西娅·哈德尔,古丽尼格尔·吾布力,郭永忠..达格列净联合沙库巴曲缬沙坦钠用于急性心肌梗死PCI术后临床观察[J].中国药业,2025,34(10):116-119,4.基金项目
新疆维吾尔自治区自然科学基金[2022D01C132]. （）
